Organization · Venture Capital
Cancer Focus Fund
Cancer Focus Fund is an oncology-focused investment fund based in Houston, Texas, that invests in cancer therapies at or near FDA Phase 1 and Phase 2 clinical trials. It collaborates with The University of Texas MD Anderson Cancer Center to provide comprehensive support for its portfolio companies.
Overview
What Cancer Focus Fund does
What Cancer Focus Fund is
Cancer Focus Fund is an oncology-focused investment fund based in Houston, Texas, that invests in cancer therapies at or near FDA Phase 1 and Phase 2 clinical trials. It collaborates with The University of Texas MD Anderson Cancer Center to provide comprehensive support for its portfolio companies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 25, 2026
Official channels
Find Cancer Focus Fund elsewhere
Open the official website or a supported primary organization account.
Capability profile
Cancer Focus Fund as a funder
Investment thesis
Cancer Focus Fund invests in late preclinical through Phase I and Phase Ib/II clinical stage oncology assets globally, leveraging its partnership with MD Anderson for access to clinical trials and scientific expertise.
Focus narrative
The fund invests in first-in-class drugs ready to advance into clinical trials, particularly in areas such as immunotherapies, CAR-T cell therapies, precision medicine, and radiotherapeutics. It is agnostic regarding the geographical origin of the therapies and focuses on novel approaches to cancer treatment.
Value beyond capital
Cancer Focus Fund provides its portfolio companies with business, management, and regulatory support, leveraging its partnership with MD Anderson to facilitate access to clinical trials and scientific expertise.
Terms and economics
- Typical check
- $4,000,000–$7,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity
- Regions
- Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 8
Portfolio context
Notable portfolio companies include: Nectin Therapeutics: Develops immunotherapeutic drugs targeting receptors from the nectin protein family for various cancers. Eisbach Bio: Focuses on precision oncology, developing drugs that disrupt tumor growth by targeting genetic vulnerabilities. ISA Pharmaceuticals: Develops synthetic immune therapies against cancer and persistent virus infections. KAHR: Leverages technology to unmask cancer and recruit targeted immune responses. Mereo BioPharma: Develops therapeutics for rare diseases and trades on NASDAQ under the symbol MREO. March Biosciences: A clinical-stage company focused on CAR-T cell strategies for hematological cancers. ImmunoGenesis: A biopharmaceutical company targeting cold tumors. Starget Pharma: Develops Smart Targeted Radioligands for precision oncology.
Common questions
What to know about Cancer Focus Fund
Upseed classifies Cancer Focus Fund under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 25, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.